AQST — Aquestive Therapeutics, Inc.

AQST Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenues: Increased to $14.4 million in Q1 2026 from $8.7 million in Q1 2025, a 66% rise.
  • License and Royalty Revenue: Rose to $5.4 million from $0.8 million, primarily due to royalty revenue from Zevra.
  • Manufacturing and Supply Revenue: Increased to $8.8 million from $7.2 million, driven by higher Suboxone revenues.
• Net Loss: Reduced to $8.1 million ($0.07 per share) from $22.9 million ($0.24 per share) in the prior year, attributed to increased revenues and decreased operating expenses.
• Non-GAAP Adjusted EBITDA Loss: Improved to $1.7 million from $17.6 million year-over-year.
• Cash Position: Ended Q1 with approximately $110 million in cash and cash equivalents, providing sufficient capital for ongoing operations and regulatory requirements.

2. Strategic Updates and Business Highlights

• Anaphylm Development: Completed a Type A meeting with the FDA and submitted a pediatric investigational plan to the EMA. The company is on track for a Q3 2026 resubmission of the NDA for Anaphylm.
• Debt Facility: Secured a $150 million debt facility with Oaktree, improving interest rate terms and extending the interest-only period, which enhances liquidity for the Anaphylm launch.
• AQST-108 Pipeline: Completed a Phase I safety study with no drug-related adverse events. Preliminary biomarker data showed potential effects on TSLP, indicating possible applications in dermatological conditions.
• Commercial Strategy: Plans to build awareness within the allergy community through a dedicated sales force and extensive conference participation (over 40 conferences planned).

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected total revenue between $46 million and $50 million, with a non-GAAP adjusted EBITDA loss projected between $35 million and $30 million.
• Data Updates: Anticipate significant data updates in August 2026, contingent on timely FDA feedback.
• Global Expansion: Plans to submit applications in Canada and Europe by the end of 2026, aiming to make Anaphylm available to nearly 1 billion people if approved in key markets.

4. Bad News, Challenges, or Points of Concern

• Regulatory Risks: The timeline for Anaphylm's resubmission and approval is dependent on FDA feedback, which introduces uncertainty.
• Market Access: Coverage and reimbursement for Anaphylm remain a concern, with the company acknowledging that achieving rapid payer coverage will take time.
• Competitive Pressures: The company is aware of the competitive landscape, particularly with existing products like Neffy, and recognizes the need for effective commercialization strategies to ensure market penetration.

5. Notable Q&A Insights

• Anaphylm Timeline: Management expressed confidence in meeting timelines for FDA resubmission, citing readiness and prior commitments from the FDA regarding protocol reviews.
• Market Research: Discussions with payers indicate significant interest in Anaphylm, but the company is preparing for the challenges of securing coverage.
• Biomarker Data: The TSLP biomarker findings for AQST-108 were described as promising, with potential implications for various dermatological conditions, although further studies are needed.
• Commercial Strategy Adjustments: The team is learning from the launch of competing products and is focused on reducing friction in physician offices to facilitate prescriptions.

Overall, AQST is positioned for significant developments in 2026, with a focus on Anaphylm's approval and market entry, while navigating regulatory and market access challenges.